bluuebunny/crossref_metadata_2025_split huggingface dataset:
Cellular Deconvolution Reveals Unique Findings in Several Cell Type Fractions Within the Basal Cell Carcinoma Tumor Microenvironment
Authors: Diaz Michael , Tran Jasmine , Natarelli Nicole , Sureshkumar Akash , Forouzandeh Mahtab 
Published: November 2023

Introduction: Despite therapeutic advancements, locally advanced and metastatic basal cell carcinomas continue to carry poor prognoses and high recurrence rates. Current treatment options remain suboptimal due to limited efficacy and associated adverse events. The objectives of this study are to 1) characterize the basal cell carcinoma immune cell microenvironment and 2) identify novel therapeutic targets.
Methods: Transcriptome data representing 25 basal cell carcinoma and 25 control tissue samples were obtained from the Gene Expression Omnibus. Cell type fraction estimates were derived by least-squares deconvolution. Population differences were determined by Mann-Whitney U test.
Results: Most significantly, two deconvolution algorithms similarly observed greater B cell infiltration in tumor samples compared to normal tissue (P<0.0001).
Conclusion: Importantly, the results of this study provide new insight into the basal cell carcinoma tumor microenvironment and nominate testable immune cell populations for future therapeutic discovery. Study limitations include sample size and applicable background prediction levels of bulk deconvolution tools.
A Comparative Outcomes Analysis: The Evolution and Growth of a Teledermatology Program to Accommodate High Patient Volumes
Authors: Doan Leandra , Kreidel, MD Marit , Benabio, MD, MBA Jeffrey , Hernandez, BS Gabriel , Engler, BS Walt , Tolbert, MD, JD, EdD, MPH Linda 
Published: November 2023

Background: Most teledermatology studies include reviews of programs on a limited scale, whereas there are fewer reports on how to expand a program to accommodate high patient volumes.
Objective: To share our insights into the growth and maintenance of a teledermatology program that sees over 100,000 cases a year.
Methods: Retrospective review of a teledermatology program between 2015 and 2022. Outcomes were compared between the initial phase from 2015-2017 and the maturation phase from 2018-2022.
Results: In 2015, the teledermatology program was piloted in 3 hospital centers and expanded to 10 more centers by 2017. There was a total of 12,385 cases in 2015, which increased to 139,110 cases in 2022. Despite the dramatic increase in number of cases, our program adapted well: the initial phase of program development resulted in 69.2% of concerns being treated remotely, compared to 70.9% of submissions in the later years, p <0.001.
Limitations: Overall generalizability as this study was performed in a large integrated health system.
Discussion: We maintain that the following can help scale a teledermatology program: 1. Communication with all interested parties; 2. Streamlined implementation of technological devices; 3. Training for dermatologists and primary providers; 4. Image guidelines to maintain photo quality.
Assessment of Wound Care Products at Major Retailers in Accordance with the American Academy of Dermatology’s Recommendations
Authors: Shimon Stephanie , Hombal Aishwarya , Romanelli Paolo 
Published: November 2023

Background: Proper wound care is important for improving healing outcomes and minimizing long-term effects of scar formation. Selection of appropriate care may be challenging for individuals due to overabundance of product selection, and conflicting evidence on common wound care products, which may pose a risk for delayed wound healing.
Objective: We aimed to assess whether wound care products sold by major retailers, specifically Walmart, Walgreens, and Target, align with the recommendations on patient support information websites provided by the American Academy of Dermatology.
Methods: A unique search inquiry was established for each major retailer, and analysis of their first aid wound care sections was performed.
Results: 393 Walgreens, 334 Walmart, and 285 Target products were included. 0% of wound cleansing products available were recommended by the academy. Petroleum-based products were represented in 61% in Walgreens, 76.2% in Walmart, and 78.4% in Target products assessed. In total, 61.6% of products in Walgreens, 57% in Walmart, and 52.7% in Target were consistent with AAD recommendations for providing appropriate wound coverage.
Conclusion: Many products sold in retailers are not recommended in managing acute minor wounds; appropriate counseling from the AAD may provide insight to optimizing wound care and scar minimization.
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial
Authors: Lebwohl Mark , Gooderham Melinda , Warren Richard B. , Thaçi Diamant , Foley Peter , Gottlieb Alice B. , Hippeli Lauren , Kisa Renata M. , Banerjee Subhashis , Griffiths Christopher EM 
Published: November 2023

Introduction: Tyrosine kinase 2 (TYK2) is an intracellular enzyme that mediates signaling of cytokines (eg, interleukin-23, Type I interferons) involved in psoriasis pathogenesis. Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the US, EU, and other countries for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. In POETYK PSO-1 (NCT03624127) and POETYK PSO-2 (NCT03611751), deucravacitinib was significantly more effective vs placebo and apremilast based on multiple endpoints. This study compared efficacy of deucravacitinib vs apremilast over 24 weeks in mean Psoriasis Area and Severity Index (PASI) improvements and evaluated absolute PASI thresholds with continuous deucravacitinib treatment from Day 1 through 52 weeks in PSO-1.
Methods: PSO-1 randomized patients 1:2:1 to oral placebo, deucravacitinib 6 mg once daily, or apremilast 30 mg twice daily; patients randomized to placebo and apremilast switched to deucravacitinib at Week 16 and Week 24, respectively. Mean change from baseline in PASI and proportions of patients achieving absolute PASI thresholds of ≤1, ≤2, ≤3, ≤4, and ≤5 were evaluated at Week 24 (deucravacitinib vs apremilast) and Week 52 (deucravacitinib only).
Results: Mean baseline PASI was similar in both groups (deucravacitinib, 21.8; apremilast, 21.4). Significantly greater mean percent reductions from baseline in PASI were observed with deucravacitinib vs apremilast at Week 24 (−77.1% vs −50.2%; P < 0.0001); mean reduction in the deucravacitinib group was maintained through Week 52 (−78.4%). Higher proportions of patients receiving deucravacitinib vs apremilast, respectively, achieved absolute PASI thresholds of ≤1 (31.3% vs 12.5%), ≤2 (41.3% vs 21.4%), ≤3 (54.8% vs 28.0%), ≤4 (63.3% vs 33.3%), and ≤5 (68.7% vs 35.7%) at Week 24 (nominal P < 0.0001 for all); response rates were maintained through Week 52 with deucravacitinib (31.3%, 45.5%, 54.5%, 61.4%, and 66.0%, respectively).
Conclusions: Deucravacitinib treatment was associated with clinically meaningful PASI outcomes that were superior to apremilast over 24 weeks and maintained through 52 weeks in patients with moderate to severe plaque psoriasis.
Safety, Tolerability and Efficacy of Tirbanibulin Ointment 1% Treatment on 100 cm2 of the Face and Scalp in Patients with Actinic Keratosis: A Phase 3 Study
Authors: Bhatia Neal , Blauvelt Andrew , Lain Edward , Jarell Abel , DuBois Janet , Tamarit Maria Luisa , Falqués Meritxell , Kiyasova Vera , Padullés Laura , Otero Raquel 
Published: November 2023

Introduction: Tirbanibulin ointment 1% has demonstrated efficacy, tolerability, and safety for AK and is approved in the US and Europe for treating AK on the face or scalp over an area up to 25 cm2 [1]. The objective of this study was to evaluate safety and tolerability of tirbanibulin applied to a larger area, a field of 100 cm2, on the face or balding scalp in adult patients with AK.
Methods: A phase 3, multicenter, open-label, single-arm study (NCT05279131) was conducted among adult patients having a treatment field on the face or balding scalp that measured 100 cm2 and contained 4-12 AKs. Patients received tirbanibulin for 5 consecutive days and were evaluated for safety, tolerability, and AK persistence until Day 57. Safety was assessed by evaluating treatment emergent adverse events (TEAEs). Tolerability endpoints included scores, 0 (absent) to 3 (severe), of 6 local signs captured at each timepoint. Exploratory efficacy was measured as percentage change from baseline (CFB) in AK lesion count.
Results: A total of 105 patients (20 sites in the US) were included in the safety analysis set (males: 69%; ≥65 years: 65%; Fitzpatrick skin type II: 63%; AK on the face: 68%). Most common local tolerability signs after 100 cm2 tirbanibulin administration were erythema (96% of patients) and flaking/scaling (85%), which were mild-to-moderate in severity, peaked at Day 5 to 8, and resolved or returned to baseline by Day 29. Severe erythema was reported only in 6% of patients and severe flaking/scaling in 9% of patients. Overall, the tolerability profile of treating a 100 cm2 area was consistent with that seen with a 25 cm2 area [1]. Most frequent TEAEs were application site pruritus (11%) and application site pain (9%), consistent with previous Phase 3 study results. No serious TEAEs related to drug were reported. Maximum local tolerability composite score was 4 out of 18, consistent with prior pivotal trials. Patients entered the study with a mean of 7.7 AKs and completed the study with a mean of 1.8 AKs, indicating outstanding efficacy. Mean percentage CFB in lesion count at Day 57 was 78%, consistent with the Phase 3 study with a 25 cm2 treatment area [1].
Conclusions: Safety, local tolerability, and efficacy in patients with AK treated with tirbanibulin over a 100 cm2 area were consistent with those previously reported in patients with AK treated in pivotal trials with tirbanibulin over a smaller area.
[1] Blauvelt A et al. N Engl J Med. 2021;384(6):512–20.
Spesolimab for Hidradenitis Suppurativa: A Proof-of-Concept Study
Authors: Alavi Afsaneh , Prens Errol , Kimball Alexa , Krueger James , Mukhopadhyay Sutirtha , Wang Hui , Ivanhoff Nathalie , Hernandez Ana Cristina , Zouboulis Christos 
Published: November 2023

Introduction: Hidradenitis suppurativa (HS) is a chronic, inflammatory disorder characterized by painful inflammatory nodules (N), abscesses (A) and draining tunnels (dT), primarily affecting intertriginous areas. Interleukin-36 (IL-36) signaling has been notably expressed within HS inflammatory lesions. To address the need for targeted therapies, this Phase IIa proof-of-clinical-concept (PoCC) study (NCT04762277) explored the effect of spesolimab, an anti-IL-36 receptor monoclonal antibody, in patients with moderate-to-severe HS.
Methods: Eligible patients (N=52) were randomized (2:1) to receive spesolimab or placebo (1200 mg intravenous dosing once weekly for three weeks [loading dose], followed by 1200 mg subcutaneous dosing every 2 weeks for 12 weeks). No formal statistical tests were performed, as this was an exploratory study. Of patients who completed the study, 45 were enrolled in an ongoing open-label extension (OLE) study (NCT04876391) with spesolimab. For each study, endpoints included change from baseline at Weeks 12 and 24 in total A, N and dT (ANdT) counts, and adverse events (AEs).
Results: Mean changes from baseline at Week 12 in dT, A and total ANdT counts were -1.30, -0.53 and -4.87 in the spesolimab arm, and 1.07, 3.07 and -0.86 in the placebo arm, respectively. Mean changes in N count were numerically similar between the spesolimab (-3.00) and placebo (-5.00) arms. Of patients with ≥1 dT at baseline, a numerically greater proportion had a decrease in dT count at Week 12 in the spesolimab (16/24, 66.7%) versus the placebo (5/13, 38.5%) arm. Least squares mean changes from baseline in total AN count at Week 12 were -38.8% and -34.7% in the spesolimab and placebo arms, respectively, which may have been affected by higher baseline AN and N counts in the spesolimab versus placebo arm. In the OLE, patients originally randomized to spesolimab (n=30) achieved sustained reductions in dT count and in International Hidradenitis Suppurativa Severity Score (IHS4) at Week 24. The safety profile of spesolimab was similar to that reported in other trials; among the 52 patients enrolled in the PoCC study, 77.8% (spesolimab) and 87.5% (placebo) of patients reported ≥1 AE. No patients receiving spesolimab reported serious AEs, and no new safety concerns were identified by Week 24. No deaths were reported.
Conclusion: Our findings show that spesolimab was well tolerated and decreased all HS lesions. These results support the development of spesolimab in HS.
This study was supported and funded by Boehringer Ingelheim.
Comparison of Study Designs for Primary Phase III Trials for Omalizumab Versus Dupilumab for Patients With Chronic Spontaneous Urticaria
Authors: Alexis Andrew , Anders Kyle , Seetasith Arpamas , Holden Michael 
Published: November 2023

Introduction
Omalizumab is currently the only biologic approved and recommended as second-line treatment for patients with chronic spontaneous urticaria (CSU). However, clinical trial programs are underway for other biologic treatments such as dupilumab. Given head-to-head trials will not be conducted, consideration of study design may be important.
Methods
Comparison of participants, interventions, outcomes, and results for phase III primary efficacy clinical trials for omalizumab versus dupilumab for patients with CSU. The omalizumab trials were ASTERIA I/II (NCT01287117 and NCT01292473) and the dupilumab trial was LIBERTY-CSU CUPID (NCT04180488) that consisted of Study A, B, and C.
Results
Participants in ASTERIA I/II were 12 to 75 years with a diagnosis of CSU refractory to H1 antihistamines. Participants in LIBERTY-CSU CUPID were 6 to 80 years (Study A and C) or 12 to 80 years (Study B) with a diagnosis of CSU refractory to H1 antihistamines, and Urticaria Activity Score (UAS)7≥16 and Itch Severity Score (ISS)7≥8 during the 7 days before randomization; Study A and C included participants who were omalizumab naïve and Study B included intolerant or incomplete responders to omalizumab. For ASTERIA I and II, the interventions were placebo or omalizumab (75mg, 150mg, 300mg) every 4 weeks for 24 and 12 weeks, respectively. For LIBERY-CSU CUPID, the interventions were placebo or dupilumab (200mg or 300mg, weight based) every 2 weeks for 24 weeks. The primary efficacy outcome for ASTERIA I/II was change from baseline in ISS7 at Week 12. The primary efficacy outcome for LIBERTY-CSU CUPID was change from baseline in ISS7 at Week 24. For the ASTERIA I primary outcome, the change from baseline in ISS7 at Week 12 was -3.6 for placebo and -6.5, -6.7, and ‑9.4 for omalizumab 75mg, 150mg, and 300mg, respectively. For the ASTERIA II primary outcome, the change from baseline in ISS7 at Week 12 was -5.1 for placebo and ‑5.9, ‑8.1, and ‑9.8 for omalizumab 75mg, 150mg, and 300mg, respectively. For the LIBERTY-CSU CUPID Study A primary outcome, the change from baseline in ISS7 at Week 24 was ‑6.0 for placebo and -10.2 for dupilumab. The LIBERTY-CSU CUPID Study B was stopped due to futility based on a pre-specified interim analysis.
Conclusion
Comparing study designs for primary clinical trials for omalizumab and dupilumab for patients with CSU will aid in the comparative analysis and clinical evaluation of final trial results.
The impact of social interactions on organisational performance in sports: A case study of Ambon City's sports organisations
Authors: Fenanlampir Albertus , Budiatin Yasmu , Hasbullah Bahmid 
Published: November 2023

Studying the impact of social interactions on sports organisations’ performance in Ambon City remains a relatively unexplored area. This research aims to address this gap by investigating the influence of social interactions among administrators, coaches, and athletes on sports organisations' performance. Additionally, it explores the disparity in performance levels between individual and team sports. The study focused on sport administrators in Ambon City affiliated with the Indonesian National Sports Committee (KONI). Fifteen participants were selected through purposive sampling, comprising administrators, coaches, and athletes from various sports branches, including athletics, taekwondo, boxing, water skiing, and football. Findings suggest that sports organisation management in Ambon City has not yet achieved optimal levels of effectiveness and facilitation, affecting the dynamics of group sports in particular. Team sports display a higher dependency on teamwork and board roles, notably the coach’s role. Despite suboptimal management, athletes retain the freedom to determine their paths to success or achievement. However, an imbalance exists between expectations and obligations in social relationships, except for the coach-athlete relationship. In summary, this study sheds light on the role of social interactions in sports organisations’ performance and highlights the differences between individual and team sports in Ambon City. These insights may serve as a foundation for more effective management strategies to enhance sports organisations’ performance in the future.
Inovasi Kue Nastar Dengan Substitusi Tepung Singkong (Manihot Esculenta) Dan Penambahan Bubuk Daun Kelor (Moringa Oleifera)
Authors: Ardiningtyas Cantika Shinta , Romadhoni Ita Fatkhur , Sutiadiningsih Any , Dewi Ila Huda Puspita 
Published: November 2023

<p class="BasicParagraph">Kue nastar ialah jenis kue kering yang dibuat dari tepung terigu, gula halus, margarin, dan kuning telur yang diisi dengan selai buah nanas. Ketergantungan Indonesia pada produk terigu impor mengakibatkan harga terigu dipasaran terbilang tinggi, sehinga perlu dilakukan pengurangan penggunaan terigu sebagai bahan utama dalam pengolahan kue nastar dengan subtitusi bahan pangan lokal seperti tepung singkong dan bubuk daun kelor. Penelitian ini menggunakan subtitusi tepung singkong sebanyak 75% dan 100% dan penambahan bubuk daun kelor 3g, 5g, dan 7g. data didapatkan melalui teknik uji organoleptik, selanjutnya dioleh menggunakan <em>uji one way anova </em>dan uji lanjutan <em>duncan.</em> Untuk mengetahui kandungan proximat, vitamin C, dan antioksidan dilakukan uji laboraturium pangan. Perhitungan harga pokok produksi dihitung dalam 1 resep yang menghasilkan 500 gram nastar. Hasil menunjukkan <sup>1</sup>Kue nastar dengan substitusi tepung singkong dan penambahan bubuk daun kelor terbaik dari uji organoleptik diperoleh dari 75% substitusi tepung singkong dan 3 gram penambahan bubuk daun kelor. <sup>2</sup>Kue kandungan gizi substitusi tepung singkong dan 3 gram penambahan bubuk daun kelor memiliki kadar abu 1,12%, protein 6,08%, lemak 3,81%, karbohidrat 53,10%, vitamin C 16,55 mg/100g dan antioksidan 123,60 mg/100g. <sup>3</sup>Harga pokok produksi kue nastar dengan substitusi tepung singkong dan penambahan bubuk daun kelor adalah Rp 106.856,-</p>
Hubungan Penggunaan Media Pembelajaran Guru Pasca Pandemi dan Motivasi Belajar Siswa
Authors: Hariyadi Hariyadi , Alimin Al Ashadi , Thomas Nova Verliana 
Published: November 2023

<div class="WordSection1"><p><em>Penelitian yang berjudul </em><em>Hubungan Penggunaan Media Pembelajaran Guru Pasca Pandemi dan Motivasi Belajar Siswa ini bertujuan untuk (1) Mendeskripsikan persepsi siswa terhadap penggunaan media pembelajaran guru </em><em>Bahasa Indonesia pasca pandemi pada motivasi belajar siswa; (2) Mendeskripsikan rata-rata motivasi belajar terhadap penggunaan media pembelajaran guru </em><em>Bahasa Indonesia pasca pandemi; (3) Mendeskripsikan h</em><em>ubungan yang signifikan penggunaan media pembelajaran guru </em><em>Bahasa Indonesia </em><em>dan motivasi belajar siswa. Metode yang digunakan ialah kuantitatif deskriptif dan bentuk penelitian ini ialah Studi Korelasi yang menggunakan pendekatan survei. Sampel didalam penelitian ini berjumlah 65 orang dari jumlah keseluruhan populasi. Penentuan sampel menggunakan teknik sampling total. Data penelitian diperoleh melalui dua instrument (1) media pembelajaran</em><em> bahasa Indonesia</em><em>, (2) motivasi belajar. Teknik analisis data yang digunakan adalah korelasi product moment. Hasil penelitian menunjukkan bahwa (1) persepsi siswa terhadap penggunaan media pembelajaran guru </em><em>bahasa Indonesia </em><em>diperoleh persentase sebesar 72,25% kategori “baik”, Adapun perolehan persentase perindikator sebesar 71,54% pada indikator penggunaan, pada indikator kesesuaian diperoleh persentase sebesar 72,21%, dan persentase pada indikator manfaat diperoleh sebesar 72,82%. (2) Rata-rata motivasi belajar siswa sebesar 78,97 kategori “sangat baik", pada indikator internal diperoleh persentase sebesar 75,68% dan pada indikator eksternal diperoleh persentase sebesar 81,70%. (3) Terdapat hubungan antara media pembelajaran</em><em> yang digunakan guru bahasa Indonesia g</em><em>dengan motivasi belajar </em><em>dengan taraf siginifikasi &gt;0,05 dan diperoleh r</em><em> </em><em>hitung sebesar 0,304 dengan sig (0,014 &gt;0,05) maka Hipotesis Alternatif (Ha) diterima dan pada sig 0,000&lt;0,05 maka Hipotesis Nol (Ho) ditolak.</em></p></div>